Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...
In trials of Wegovy, up to 40% of weight loss was from a decrease in lean or fat-free mass, rather than excess fat. These experimental medicines are still a few years from possible approval. Veru ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% ...
Veru Veru's oral drug ... In a mid-stage study, patients who received the drug along with Wegovy lost 71% less lean, or muscle, mass on average than those who received Wegovy and a placebo ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Veru had a pre-IND meeting with the FDA Division ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular outcomes ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as ...
Veru had a pre-IND meeting with the FDA Division of Cardiology ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results